Cigna Investments’s Charles River Laboratories CRL Stock Holding History

Cigna Investments’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-877	Closed	-$249K	–	484
2022 Q1	$249K	Sell	877 -269	-23%	-$82.9K	0.03%	503
2021 Q4	$431K	Sell	1,146 -503	-31%	-$195K	0.03%	412
2021 Q3	$681K	Hold	1,649	–	–	0.05%	336
2021 Q2	$611K	Sell	1,649 -300	-15%	-$100K	0.04%	378
2021 Q1	$565K	Buy	1,949 +158	+9%	+$43.9K	0.04%	412
2020 Q4	$447K	Buy	1,791 +175	+11%	+$41.7K	0.03%	443
2020 Q3	$366K	Hold	1,616	–	–	0.04%	433
2020 Q2	$282K	Buy	+1,616	New	+$258K	0.03%	565
2019 Q2	–	Sell	-1,384	Closed	-$201K	–	672
2019 Q1	$201K	Buy	+1,384	New	+$182K	0.02%	646
2017 Q4	–	Sell	-1,903	Closed	-$206K	–	900
2017 Q3	$206K	Buy	+1,903	New	+$196K	0.01%	830

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cigna Investments's CRL Position: Q2 2022 in Review

Cigna Investments sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 877 shares — an estimated $249K sold.

Cigna Investments first reported a position in CRL in Q3 2017 and held it in 10 quarters. The position peaked at $681K in Q3 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

Cigna Investments reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
Cigna Investments sold 877 Charles River Laboratories shares in Q2 2022, an estimated $249K.
Cigna Investments first reported a position in Charles River Laboratories in Q3 2017 and held it in 10 quarters.
Cigna Investments's Charles River Laboratories position peaked at $681K in Q3 2021.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Cigna Investments's 13F filing for Q2 2022, filed 15 Aug 2022.